From: Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study
QOL score
n
Pretreatment
Posttreatment
DE + rh-endostatin
35
53.12 ± 3.43
53.18 ± 4.41
DE
33
53.55 ± 4.87
51.76 ± 5.43